{"id":68003,"date":"2026-10-28T19:12:54","date_gmt":"2026-10-28T13:42:54","guid":{"rendered":"https:\/\/johnsonfrancis.org\/professional\/?p=68003"},"modified":"2026-10-28T19:13:00","modified_gmt":"2026-10-28T13:43:00","slug":"new-series-of-interactive-cardiology-mcqs-17","status":"publish","type":"post","link":"https:\/\/johnsonfrancis.org\/professional\/new-series-of-interactive-cardiology-mcqs-17\/","title":{"rendered":"New Series of Interactive Cardiology MCQs 17"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><\/p>\n\n\n\n<!-- Cardiology MCQs Part 17 (Full 25 Questions) - WordPress Safe Custom HTML Block -->\n<script src=\"https:\/\/cdn.tailwindcss.com?plugins=forms,typography,aspect-ratio\"><\/script>\n<script>\n  tailwind.config = {\n    corePlugins: { preflight: false }\n  }\n<\/script>\n\n<div id=\"mcq17-quiz-wrapper\" class=\"font-sans bg-slate-950 text-slate-100 p-4 md:p-8 rounded-3xl max-w-4xl mx-auto shadow-2xl relative overflow-hidden my-8 border border-solid border-cyan-500\/20\" style=\"box-sizing: border-box;\">\n  \n  <!-- Background Accents -->\n  <div class=\"absolute top-0 left-0 w-full h-full pointer-events-none opacity-10 bg-[radial-gradient(ellipse_at_center,_var(--tw-gradient-stops))] from-cyan-500 via-blue-900 to-slate-950\"><\/div>\n  \n  <!-- Header Banner -->\n  <div class=\"relative text-center pb-6 border-b border-solid border-cyan-500\/25 mb-8\">\n    <div class=\"inline-block bg-gradient-to-r from-blue-500 via-cyan-600 to-teal-600 text-white font-black text-xs md:text-sm px-4 py-1.5 rounded-full uppercase tracking-wider shadow-lg mb-3 animate-pulse\">\n      \ud83e\udec0 Advanced Cardiology Series &#8211; Part 17\n    <\/div>\n    <h1 class=\"text-3xl md:text-5xl font-extrabold tracking-tight text-transparent bg-clip-text bg-gradient-to-r from-cyan-300 via-blue-400 to-indigo-400 m-0\">\n      Interactive Cardiology MCQs #17\n    <\/h1>\n    <p class=\"text-sm md:text-lg text-slate-300 mt-2 max-w-2xl mx-auto font-medium\">\n      Post-Graduate Level Clinical, EP, Structural &amp; Hemodynamics Masterclass\n    <\/p>\n  <\/div>\n\n  <!-- Real-Time Floating Scoreboard -->\n  <div class=\"sticky top-4 z-40 bg-slate-900\/90 backdrop-blur-md border-2 border-solid border-cyan-500\/40 rounded-2xl p-4 mb-8 shadow-xl flex flex-wrap items-center justify-between gap-4\">\n    <div class=\"flex items-center gap-3\">\n      <div class=\"text-3xl\">\ud83c\udfc5<\/div>\n      <div>\n        <div class=\"text-[10px] uppercase font-extrabold tracking-widest text-cyan-300\">Live Scoreboard<\/div>\n        <div class=\"text-lg md:text-2xl font-black text-blue-300 flex items-center gap-1\">\n          <span id=\"mcq17-correct-count\">0<\/span><span class=\"text-slate-500 text-sm md:text-lg\">\/ 25 Correct<\/span>\n        <\/div>\n      <\/div>\n    <\/div>\n    <div class=\"flex items-center gap-2 bg-slate-950\/80 px-4 py-2 rounded-xl border border-solid border-slate-800\">\n      <span class=\"text-xs font-bold text-slate-400 uppercase tracking-wider\">Progress:<\/span>\n      <div class=\"w-24 md:w-36 bg-slate-800 h-3 rounded-full overflow-hidden\">\n        <div id=\"mcq17-progress-bar\" class=\"bg-gradient-to-r from-cyan-500 to-blue-500 h-full w-0 transition-all duration-300 rounded-full\"><\/div>\n      <\/div>\n      <span class=\"text-xs font-bold text-blue-300\"><span id=\"mcq17-answered-count\">0<\/span>\/25<\/span>\n    <\/div>\n  <\/div>\n\n  <!-- Quiz Questions Container -->\n  <div class=\"space-y-8 relative\">\n\n    <!-- Q1 -->\n    <div class=\"quiz-card bg-slate-900\/60 border border-solid border-slate-800 rounded-2xl p-5 md:p-6 shadow-lg transition-all duration-300\" data-answered=\"false\">\n      <div class=\"flex items-start gap-3 mb-4\">\n        <span class=\"bg-cyan-950 text-blue-300 font-extrabold px-3 py-1.5 rounded-lg text-sm border border-solid border-cyan-500\/30\">Q1<\/span>\n        <h3 class=\"text-lg md:text-xl font-bold text-slate-100 m-0 leading-snug\">\n          During coronary angiography, Fractional Flow Reserve (FFR) is measured to assess the hemodynamic significance of an intermediate coronary stenosis. What is the standard FFR cut-off value below which revascularization is indicated to improve outcomes?\n        <\/h3>\n      <\/div>\n      <div class=\"grid grid-cols-1 md:grid-cols-2 gap-3 mb-4\">\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"This cut-off is used for resting indices like iFR (Instantaneous Wave-free Ratio), where &lt;= 0.89 is significant. Reference: 2021 ACC\/AHA\/SCAI Guideline for Coronary Artery Revascularization.\">A) FFR &lt;= 0.89<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"true\" data-explanation=\"Based on the FAME trials, an FFR of &lt;= 0.80 indicates a hemodynamically significant stenosis causing ischemia, and justifies revascularization (PCI or CABG). An FFR &gt; 0.80 suggests deferring revascularization is safe. Reference: 2021 ACC\/AHA\/SCAI Guideline for Coronary Artery Revascularization.\">B) FFR &lt;= 0.80<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"This value is too low and would result in undertreating many ischemic lesions. Reference: 2021 ACC\/AHA\/SCAI Guideline for Coronary Artery Revascularization.\">C) FFR &lt;= 0.70<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"This indicates essentially normal coronary flow with a 5% drop, not a significant stenosis. Reference: 2021 ACC\/AHA\/SCAI Guideline for Coronary Artery Revascularization.\">D) FFR &lt;= 0.95<\/button>\n      <\/div>\n      <div class=\"feedback-box hidden p-4 rounded-xl text-sm md:text-base leading-relaxed\"><\/div>\n    <\/div>\n\n    <!-- Q2 -->\n    <div class=\"quiz-card bg-slate-900\/60 border border-solid border-slate-800 rounded-2xl p-5 md:p-6 shadow-lg transition-all duration-300\" data-answered=\"false\">\n      <div class=\"flex items-start gap-3 mb-4\">\n        <span class=\"bg-cyan-950 text-blue-300 font-extrabold px-3 py-1.5 rounded-lg text-sm border border-solid border-cyan-500\/30\">Q2<\/span>\n        <h3 class=\"text-lg md:text-xl font-bold text-slate-100 m-0 leading-snug\">\n          A patient presents with chest pain that has now resolved. The ECG shows deep, symmetrically inverted T waves in leads V2 and V3 without Q waves or significant ST elevation. This is recognized as Wellens&#8217; Syndrome. What does this specific ECG pattern indicate?\n        <\/h3>\n      <\/div>\n      <div class=\"grid grid-cols-1 md:grid-cols-2 gap-3 mb-4\">\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"Posterior MI typically presents with ST depression and tall R waves in V1-V3, not deep inverted T waves. Reference: 2023 ESC Guidelines for the management of ACS.\">A) Acute occlusion of the posterior descending artery (PDA).<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"Pulmonary embolism may cause T wave inversions in V1-V4, but Wellens' syndrome is an ischemic phenomenon. Reference: 2023 ESC Guidelines for the management of ACS.\">B) Acute massive pulmonary embolism with right ventricular strain.<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"Vasospasm typically causes transient ST segment elevation (Prinzmetal angina). Reference: 2023 ESC Guidelines for the management of ACS.\">C) Coronary vasospasm of the right coronary artery.<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"true\" data-explanation=\"Wellens' syndrome (Type B features deep inverted T waves, Type A features biphasic T waves in V2-V3) is highly specific for a critical, high-grade stenosis of the proximal Left Anterior Descending (LAD) artery. These patients are at imminent risk of extensive anterior wall MI and require urgent angiography. Reference: 2023 ESC Guidelines for the management of ACS.\">D) Critical stenosis of the proximal Left Anterior Descending (LAD) artery.<\/button>\n      <\/div>\n      <div class=\"feedback-box hidden p-4 rounded-xl text-sm md:text-base leading-relaxed\"><\/div>\n    <\/div>\n\n    <!-- Q3 -->\n    <div class=\"quiz-card bg-slate-900\/60 border border-solid border-slate-800 rounded-2xl p-5 md:p-6 shadow-lg transition-all duration-300\" data-answered=\"false\">\n      <div class=\"flex items-start gap-3 mb-4\">\n        <span class=\"bg-cyan-950 text-blue-300 font-extrabold px-3 py-1.5 rounded-lg text-sm border border-solid border-cyan-500\/30\">Q3<\/span>\n        <h3 class=\"text-lg md:text-xl font-bold text-slate-100 m-0 leading-snug\">\n          The ATTR-ACT trial demonstrated a significant reduction in mortality and cardiovascular hospitalizations for patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM) using Tafamidis. What is the specific mechanism of action of Tafamidis?\n        <\/h3>\n      <\/div>\n      <div class=\"grid grid-cols-1 md:grid-cols-2 gap-3 mb-4\">\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"true\" data-explanation=\"Tafamidis is a transthyretin (TTR) kinetic stabilizer. It binds to the native TTR tetramer, preventing its dissociation into unstable monomers, which is the rate-limiting step in amyloid fibril misfolding and deposition in the myocardium. Reference: 2022 AHA\/ACC\/HFSA Guideline for the Management of Heart Failure.\">A) It binds and stabilizes the transthyretin tetramer, preventing its dissociation into amyloidogenic monomers.<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"This describes the mechanism of RNA interference therapies like Patisiran or Inotersen. Reference: 2022 AHA\/ACC\/HFSA Guideline for the Management of Heart Failure.\">B) It is a small interfering RNA (siRNA) that halts the hepatic production of the transthyretin protein.<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"This describes therapies targeting AL (light chain) amyloidosis, such as Daratumumab or bortezomib. Reference: 2022 AHA\/ACC\/HFSA Guideline for the Management of Heart Failure.\">C) It directly targets and destroys clonal plasma cells in the bone marrow.<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"There are currently no approved therapies that actively dissolve established amyloid fibrils in the heart. Reference: 2022 AHA\/ACC\/HFSA Guideline for the Management of Heart Failure.\">D) It acts as an active fibril disruptor, directly dissolving already deposited amyloid fibrils in the myocardium.<\/button>\n      <\/div>\n      <div class=\"feedback-box hidden p-4 rounded-xl text-sm md:text-base leading-relaxed\"><\/div>\n    <\/div>\n\n    <!-- Q4 -->\n    <div class=\"quiz-card bg-slate-900\/60 border border-solid border-slate-800 rounded-2xl p-5 md:p-6 shadow-lg transition-all duration-300\" data-answered=\"false\">\n      <div class=\"flex items-start gap-3 mb-4\">\n        <span class=\"bg-cyan-950 text-blue-300 font-extrabold px-3 py-1.5 rounded-lg text-sm border border-solid border-cyan-500\/30\">Q4<\/span>\n        <h3 class=\"text-lg md:text-xl font-bold text-slate-100 m-0 leading-snug\">\n          An otherwise healthy 30-year-old presents with palpitations. The ECG shows a wide-complex tachycardia. Which of the following morphologic patterns strongly points toward Idiopathic Right Ventricular Outflow Tract (RVOT) Ventricular Tachycardia?\n        <\/h3>\n      <\/div>\n      <div class=\"grid grid-cols-1 md:grid-cols-2 gap-3 mb-4\">\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"RBBB with superior axis suggests Left Posterior Fascicular VT (idiopathic LV VT). Reference: 2019 HRS\/EHRA\/APHRS\/LAHRS Expert Consensus Statement.\">A) Right Bundle Branch Block (RBBB) morphology with a superior axis (negative in II, III, aVF).<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"true\" data-explanation=\"RVOT VT originates from the anterior, superior portion of the right ventricle. Therefore, electrical activation travels from right to left (creating an LBBB morphology in V1) and from superior to inferior (creating an inferior axis with tall positive R waves in leads II, III, and aVF). Reference: 2019 HRS\/EHRA\/APHRS\/LAHRS Expert Consensus Statement.\">B) Left Bundle Branch Block (LBBB) morphology with an inferior axis (positive in II, III, aVF).<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"RBBB with right axis deviation suggests left anterior fascicular VT. Reference: 2019 HRS\/EHRA\/APHRS\/LAHRS Expert Consensus Statement.\">C) Right Bundle Branch Block (RBBB) morphology with right axis deviation.<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"LBBB with superior axis suggests an origin from the inferior aspect of the RV (e.g., RV inflow tract or inferior wall). Reference: 2019 HRS\/EHRA\/APHRS\/LAHRS Expert Consensus Statement.\">D) Left Bundle Branch Block (LBBB) morphology with a superior axis (negative in II, III, aVF).<\/button>\n      <\/div>\n      <div class=\"feedback-box hidden p-4 rounded-xl text-sm md:text-base leading-relaxed\"><\/div>\n    <\/div>\n\n    <!-- Q5 -->\n    <div class=\"quiz-card bg-slate-900\/60 border border-solid border-slate-800 rounded-2xl p-5 md:p-6 shadow-lg transition-all duration-300\" data-answered=\"false\">\n      <div class=\"flex items-start gap-3 mb-4\">\n        <span class=\"bg-cyan-950 text-blue-300 font-extrabold px-3 py-1.5 rounded-lg text-sm border border-solid border-cyan-500\/30\">Q5<\/span>\n        <h3 class=\"text-lg md:text-xl font-bold text-slate-100 m-0 leading-snug\">\n          In a patient with classical low-flow, low-gradient severe aortic stenosis (LVEF &lt; 40%, AVA &lt; 1.0 cm\u00b2, Mean Gradient &lt; 40 mmHg), a low-dose dobutamine stress echocardiogram is performed. What specific finding defines the presence of &#8220;contractile reserve&#8221;?\n        <\/h3>\n      <\/div>\n      <div class=\"grid grid-cols-1 md:grid-cols-2 gap-3 mb-4\">\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"An increase in mean gradient without context does not define flow reserve; flow reserve is strictly volume-based. Reference: 2020 ACC\/AHA Guideline for the Management of Patients With Valvular Heart Disease.\">A) An absolute increase in the mean transaortic gradient by &gt; 20 mmHg.<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"true\" data-explanation=\"Contractile (or flow) reserve during dobutamine stress echo is defined by an increase in stroke volume (SV) by &gt;= 20% from baseline. If SV increases by &gt;= 20% and the AVA remains &lt; 1.0 cm\u00b2 while the gradient rises &gt; 40 mmHg, it confirms true severe AS. Lack of flow reserve increases surgical risk but does not contraindicate TAVR. Reference: 2020 ACC\/AHA Guideline for the Management of Patients With Valvular Heart Disease.\">B) An increase in Stroke Volume by &gt;= 20% compared to baseline.<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"A normalization of EF is not required to define contractile reserve. Reference: 2020 ACC\/AHA Guideline for the Management of Patients With Valvular Heart Disease.\">C) A normalization of the Left Ventricular Ejection Fraction (LVEF &gt;= 50%).<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"If the AVA increases to &gt; 1.0 cm\u00b2, this indicates pseudo-severe AS (the valve is actually flexible and just wasn't opening fully due to poor LV thrust). Reference: 2020 ACC\/AHA Guideline for the Management of Patients With Valvular Heart Disease.\">D) An increase in the Aortic Valve Area (AVA) to &gt; 1.2 cm\u00b2.<\/button>\n      <\/div>\n      <div class=\"feedback-box hidden p-4 rounded-xl text-sm md:text-base leading-relaxed\"><\/div>\n    <\/div>\n\n    <!-- Q6 -->\n    <div class=\"quiz-card bg-slate-900\/60 border border-solid border-slate-800 rounded-2xl p-5 md:p-6 shadow-lg transition-all duration-300\" data-answered=\"false\">\n      <div class=\"flex items-start gap-3 mb-4\">\n        <span class=\"bg-cyan-950 text-blue-300 font-extrabold px-3 py-1.5 rounded-lg text-sm border border-solid border-cyan-500\/30\">Q6<\/span>\n        <h3 class=\"text-lg md:text-xl font-bold text-slate-100 m-0 leading-snug\">\n          During physical examination of the jugular venous pulse (JVP), the intermittent presence of giant &#8220;Cannon A waves&#8221; is a classic sign of which hemodynamic phenomenon?\n        <\/h3>\n      <\/div>\n      <div class=\"grid grid-cols-1 md:grid-cols-2 gap-3 mb-4\">\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"Atrial fibrillation results in the complete loss of 'A' waves because there is no coordinated atrial contraction. Reference: Braunwald's Heart Disease: A Textbook of Cardiovascular Medicine.\">A) Uncontrolled Atrial Fibrillation.<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"true\" data-explanation=\"Cannon A waves occur when the right atrium contracts against a closed tricuspid valve. Intermittent cannon A waves are the clinical hallmark of atrioventricular (AV) dissociation, as seen in complete (third-degree) heart block or ventricular tachycardia. Reference: Braunwald's Heart Disease: A Textbook of Cardiovascular Medicine.\">B) Atrioventricular (AV) dissociation (e.g., complete heart block or VT).<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"Severe TR causes giant 'v' (or 'cv') waves due to systolic regurgitation of blood into the right atrium, not 'a' waves. Reference: Braunwald's Heart Disease: A Textbook of Cardiovascular Medicine.\">C) Severe primary Tricuspid Regurgitation.<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"Constrictive pericarditis is associated with a prominent, rapid 'y' descent (Friedreich's sign) in the JVP. Reference: Braunwald's Heart Disease: A Textbook of Cardiovascular Medicine.\">D) Constrictive Pericarditis.<\/button>\n      <\/div>\n      <div class=\"feedback-box hidden p-4 rounded-xl text-sm md:text-base leading-relaxed\"><\/div>\n    <\/div>\n\n    <!-- Q7 -->\n    <div class=\"quiz-card bg-slate-900\/60 border border-solid border-slate-800 rounded-2xl p-5 md:p-6 shadow-lg transition-all duration-300\" data-answered=\"false\">\n      <div class=\"flex items-start gap-3 mb-4\">\n        <span class=\"bg-cyan-950 text-blue-300 font-extrabold px-3 py-1.5 rounded-lg text-sm border border-solid border-cyan-500\/30\">Q7<\/span>\n        <h3 class=\"text-lg md:text-xl font-bold text-slate-100 m-0 leading-snug\">\n          A 14-year-old female is diagnosed with Congenital Long QT Syndrome Type 2 (LQT2). Which specific trigger is most classically associated with initiating Torsades de Pointes in this specific genotype?\n        <\/h3>\n      <\/div>\n      <div class=\"grid grid-cols-1 md:grid-cols-2 gap-3 mb-4\">\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"Swimming and intense physical exertion are the classic triggers for Long QT Syndrome Type 1 (KCNQ1 mutation). Reference: 2022 ESC Guidelines for the management of patients with ventricular arrhythmias.\">A) Swimming or intense physical exertion.<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"true\" data-explanation=\"LQT2 (associated with the KCNH2 gene mutation affecting the IKr current) is exquisitely sensitive to sudden auditory stimuli. Sudden loud noises like alarm clocks, ringing telephones, or crying babies are the classic triggers for arrhythmic events in LQT2. Reference: 2022 ESC Guidelines for the management of patients with ventricular arrhythmias.\">B) Sudden loud auditory stimuli (e.g., alarm clocks, ringing telephones).<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"Events occurring during restful sleep or profound bradycardia are classic for Long QT Syndrome Type 3 (SCN5A mutation). Reference: 2022 ESC Guidelines for the management of patients with ventricular arrhythmias.\">C) Restful sleep and profound bradycardia.<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"Hypercalcemia shortens the QT interval and is not a trigger for LQTS. Reference: 2022 ESC Guidelines for the management of patients with ventricular arrhythmias.\">D) High calcium meals.<\/button>\n      <\/div>\n      <div class=\"feedback-box hidden p-4 rounded-xl text-sm md:text-base leading-relaxed\"><\/div>\n    <\/div>\n\n    <!-- Q8 -->\n    <div class=\"quiz-card bg-slate-900\/60 border border-solid border-slate-800 rounded-2xl p-5 md:p-6 shadow-lg transition-all duration-300\" data-answered=\"false\">\n      <div class=\"flex items-start gap-3 mb-4\">\n        <span class=\"bg-cyan-950 text-blue-300 font-extrabold px-3 py-1.5 rounded-lg text-sm border border-solid border-cyan-500\/30\">Q8<\/span>\n        <h3 class=\"text-lg md:text-xl font-bold text-slate-100 m-0 leading-snug\">\n          On Cardiac MRI, what is the characteristic distribution of Late Gadolinium Enhancement (LGE) seen in patients with Hypertrophic Cardiomyopathy (HCM)?\n        <\/h3>\n      <\/div>\n      <div class=\"grid grid-cols-1 md:grid-cols-2 gap-3 mb-4\">\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"Diffuse, global subendocardial enhancement is the classic hallmark of Cardiac Amyloidosis. Reference: 2024 AHA\/ACC Guideline for the Management of Hypertrophic Cardiomyopathy.\">A) Global, diffuse subendocardial enhancement not restricted to a specific coronary territory.<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"true\" data-explanation=\"In Hypertrophic Cardiomyopathy, LGE representing focal myocardial fibrosis is characteristically patchy and mid-wall, predominantly localized to the most hypertrophied segments (typically the septum) and classically at the right ventricular insertion points (hinge points). Reference: 2024 AHA\/ACC Guideline for the Management of Hypertrophic Cardiomyopathy.\">B) Patchy, mid-wall enhancement predominantly at the hypertrophied septum and right ventricular insertion points.<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"Transmural enhancement matching a specific coronary artery territory indicates a prior myocardial infarction (ischemic scar). Reference: 2024 AHA\/ACC Guideline for the Management of Hypertrophic Cardiomyopathy.\">C) Transmural enhancement cleanly matching the territory of the Left Anterior Descending artery.<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"Subepicardial enhancement (especially inferolateral wall) is typical of acute myocarditis. Reference: 2024 AHA\/ACC Guideline for the Management of Hypertrophic Cardiomyopathy.\">D) Isolated subepicardial enhancement of the lateral wall.<\/button>\n      <\/div>\n      <div class=\"feedback-box hidden p-4 rounded-xl text-sm md:text-base leading-relaxed\"><\/div>\n    <\/div>\n\n    <!-- Q9 -->\n    <div class=\"quiz-card bg-slate-900\/60 border border-solid border-slate-800 rounded-2xl p-5 md:p-6 shadow-lg transition-all duration-300\" data-answered=\"false\">\n      <div class=\"flex items-start gap-3 mb-4\">\n        <span class=\"bg-cyan-950 text-blue-300 font-extrabold px-3 py-1.5 rounded-lg text-sm border border-solid border-cyan-500\/30\">Q9<\/span>\n        <h3 class=\"text-lg md:text-xl font-bold text-slate-100 m-0 leading-snug\">\n          According to ACC\/AHA guidelines, what is the target International Normalized Ratio (INR) for a patient receiving a modern bileaflet mechanical Mitral Valve replacement (with no other thromboembolic risk factors)?\n        <\/h3>\n      <\/div>\n      <div class=\"grid grid-cols-1 md:grid-cols-2 gap-3 mb-4\">\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"An INR of 2.5 (range 2.0-3.0) is the target for modern bileaflet mechanical AORTIC valves (without additional risk factors). Reference: 2020 ACC\/AHA Guideline for the Management of Patients With Valvular Heart Disease.\">A) INR 2.5 (range 2.0 &#8211; 3.0)<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"true\" data-explanation=\"Because flow across the mitral valve is slower and less pulsatile than the aortic valve, the risk of thrombosis is higher. Therefore, ALL mechanical mitral valves require a higher target INR of 3.0 (acceptable range 2.5 to 3.5), regardless of the valve type or other risk factors. Reference: 2020 ACC\/AHA Guideline for the Management of Patients With Valvular Heart Disease.\">B) INR 3.0 (range 2.5 &#8211; 3.5)<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"An INR target of 3.5 is generally not recommended as standard monotherapy due to excessive bleeding risks. Reference: 2020 ACC\/AHA Guideline for the Management of Patients With Valvular Heart Disease.\">C) INR 3.5 (range 3.0 &#8211; 4.0)<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"This is the target range for bioprosthetic valves (if anticoagulated for the first 3 months) or DVT prophylaxis. Reference: 2020 ACC\/AHA Guideline for the Management of Patients With Valvular Heart Disease.\">D) INR 2.0 (range 1.5 &#8211; 2.5)<\/button>\n      <\/div>\n      <div class=\"feedback-box hidden p-4 rounded-xl text-sm md:text-base leading-relaxed\"><\/div>\n    <\/div>\n\n    <!-- Q10 -->\n    <div class=\"quiz-card bg-slate-900\/60 border border-solid border-slate-800 rounded-2xl p-5 md:p-6 shadow-lg transition-all duration-300\" data-answered=\"false\">\n      <div class=\"flex items-start gap-3 mb-4\">\n        <span class=\"bg-cyan-950 text-blue-300 font-extrabold px-3 py-1.5 rounded-lg text-sm border border-solid border-cyan-500\/30\">Q10<\/span>\n        <h3 class=\"text-lg md:text-xl font-bold text-slate-100 m-0 leading-snug\">\n          During an echocardiogram, continuous-wave Doppler of the aortic valve reveals Aortic Regurgitation (AR). Which Pressure Half-Time (PHT) value indicates that the aortic regurgitation is severe?\n        <\/h3>\n      <\/div>\n      <div class=\"grid grid-cols-1 md:grid-cols-2 gap-3 mb-4\">\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"A PHT &gt; 500 ms indicates a slow equalization of pressures, characteristic of mild aortic regurgitation. Reference: 2017 ASE Guidelines for Noninvasive Evaluation of Native Valvular Regurgitation.\">A) PHT &gt; 500 ms<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"This is typically an intermediate value (moderate AR). Reference: 2017 ASE Guidelines for Noninvasive Evaluation of Native Valvular Regurgitation.\">B) PHT between 300 ms and 450 ms<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"true\" data-explanation=\"Pressure Half-Time measures how quickly the pressure gradient between the aorta and LV drops during diastole. In severe AR, the massive regurgitant volume causes rapid equalization of aortic and LV diastolic pressures, resulting in a steep slope and a short PHT of &lt; 200 ms. Reference: 2017 ASE Guidelines for Noninvasive Evaluation of Native Valvular Regurgitation.\">C) PHT &lt; 200 ms<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"While extremely low PHTs occur in severe AR, the validated ASE guideline cutoff for 'severe' begins at &lt; 200 ms. Reference: 2017 ASE Guidelines for Noninvasive Evaluation of Native Valvular Regurgitation.\">D) PHT exactly at 250 ms<\/button>\n      <\/div>\n      <div class=\"feedback-box hidden p-4 rounded-xl text-sm md:text-base leading-relaxed\"><\/div>\n    <\/div>\n\n    <!-- Q11 -->\n    <div class=\"quiz-card bg-slate-900\/60 border border-solid border-slate-800 rounded-2xl p-5 md:p-6 shadow-lg transition-all duration-300\" data-answered=\"false\">\n      <div class=\"flex items-start gap-3 mb-4\">\n        <span class=\"bg-cyan-950 text-blue-300 font-extrabold px-3 py-1.5 rounded-lg text-sm border border-solid border-cyan-500\/30\">Q11<\/span>\n        <h3 class=\"text-lg md:text-xl font-bold text-slate-100 m-0 leading-snug\">\n          Drugs like Alirocumab and Evolocumab are powerful lipid-lowering agents. What is the specific cellular mechanism of PCSK9 inhibitors?\n        <\/h3>\n      <\/div>\n      <div class=\"grid grid-cols-1 md:grid-cols-2 gap-3 mb-4\">\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"This is the mechanism of statins (HMG-CoA reductase inhibitors). Reference: 2018 AHA\/ACC Guideline on the Management of Blood Cholesterol.\">A) They inhibit HMG-CoA reductase, halting de novo cholesterol synthesis in the liver.<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"This is the mechanism of Ezetimibe. Reference: 2018 AHA\/ACC Guideline on the Management of Blood Cholesterol.\">B) They inhibit the Niemann-Pick C1-Like 1 (NPC1L1) transporter in the intestines.<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"true\" data-explanation=\"PCSK9 is an enzyme that binds to LDL receptors on hepatocytes, marking them for lysosomal degradation. PCSK9 inhibitors block this enzyme, allowing LDL receptors to be recycled back to the liver surface, profoundly increasing the clearance of LDL from the blood. Reference: 2018 AHA\/ACC Guideline on the Management of Blood Cholesterol.\">C) They bind to PCSK9, preventing it from targeting hepatocyte LDL receptors for lysosomal degradation.<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"This describes the mechanism of Bempedoic acid. Reference: 2018 AHA\/ACC Guideline on the Management of Blood Cholesterol.\">D) They inhibit ATP citrate lyase, an enzyme upstream of HMG-CoA reductase.<\/button>\n      <\/div>\n      <div class=\"feedback-box hidden p-4 rounded-xl text-sm md:text-base leading-relaxed\"><\/div>\n    <\/div>\n\n    <!-- Q12 -->\n    <div class=\"quiz-card bg-slate-900\/60 border border-solid border-slate-800 rounded-2xl p-5 md:p-6 shadow-lg transition-all duration-300\" data-answered=\"false\">\n      <div class=\"flex items-start gap-3 mb-4\">\n        <span class=\"bg-cyan-950 text-blue-300 font-extrabold px-3 py-1.5 rounded-lg text-sm border border-solid border-cyan-500\/30\">Q12<\/span>\n        <h3 class=\"text-lg md:text-xl font-bold text-slate-100 m-0 leading-snug\">\n          On an ECG, typical Cavo-Tricuspid Isthmus (CTI)-dependent counterclockwise Atrial Flutter exhibits a very specific &#8220;saw-tooth&#8221; wave morphology in the leads. What is this classic pattern?\n        <\/h3>\n      <\/div>\n      <div class=\"grid grid-cols-1 md:grid-cols-2 gap-3 mb-4\">\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"true\" data-explanation=\"In typical counterclockwise CTI-dependent atrial flutter, the reentrant circuit travels up the interatrial septum and down the right atrial free wall. This depolarization moving away from the inferior leads causes negative (downward) saw-tooth flutter waves in leads II, III, and aVF, and a positive deflection in lead V1. Reference: 2019 ESC Guidelines for the management of patients with supraventricular tachycardia.\">A) Negative flutter waves in the inferior leads (II, III, aVF) and positive flutter waves in V1.<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"This is the pattern for atypical (clockwise) CTI-dependent atrial flutter. Reference: 2019 ESC Guidelines for the management of patients with supraventricular tachycardia.\">B) Positive flutter waves in the inferior leads (II, III, aVF) and negative flutter waves in V1.<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"This pattern does not match the typical CTI vector. Reference: 2019 ESC Guidelines for the management of patients with supraventricular tachycardia.\">C) Positive flutter waves in leads I and aVL only.<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"Flutter waves are organized macro-reentrant circuits, not chaotic baseline undulations (which define atrial fibrillation). Reference: 2019 ESC Guidelines for the management of patients with supraventricular tachycardia.\">D) Chaotic, varying flutter waves that change vector beat-to-beat across all leads.<\/button>\n      <\/div>\n      <div class=\"feedback-box hidden p-4 rounded-xl text-sm md:text-base leading-relaxed\"><\/div>\n    <\/div>\n\n    <!-- Q13 -->\n    <div class=\"quiz-card bg-slate-900\/60 border border-solid border-slate-800 rounded-2xl p-5 md:p-6 shadow-lg transition-all duration-300\" data-answered=\"false\">\n      <div class=\"flex items-start gap-3 mb-4\">\n        <span class=\"bg-cyan-950 text-blue-300 font-extrabold px-3 py-1.5 rounded-lg text-sm border border-solid border-cyan-500\/30\">Q13<\/span>\n        <h3 class=\"text-lg md:text-xl font-bold text-slate-100 m-0 leading-snug\">\n          A 22-year-old patient who underwent a Fontan palliation for single ventricle physiology in childhood presents with severe edema, hypoalbuminemia, and chronic diarrhea. What dreaded complication of the Fontan circulation is this patient exhibiting?\n        <\/h3>\n      <\/div>\n      <div class=\"grid grid-cols-1 md:grid-cols-2 gap-3 mb-4\">\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"While cirrhosis can happen in Fontan patients (cardiac cirrhosis), it doesn't primarily present with chronic diarrhea as the defining feature. Reference: 2020 ESC Guidelines for the management of adult congenital heart disease.\">A) Fontan-associated hepatocellular carcinoma.<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"Plastic bronchitis presents with coughing up thick, branching bronchial casts, not diarrhea. Reference: 2020 ESC Guidelines for the management of adult congenital heart disease.\">B) Plastic Bronchitis.<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"true\" data-explanation=\"Protein-Losing Enteropathy (PLE) is a severe, late complication of the Fontan circulation. Chronically elevated central venous pressures lead to lymphatic congestion and leakage of serum proteins into the gut lumen, causing severe hypoalbuminemia, chronic diarrhea, and profound edema. Reference: 2020 ESC Guidelines for the management of adult congenital heart disease.\">C) Protein-Losing Enteropathy (PLE).<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"Eisenmenger syndrome involves pulmonary vascular disease causing right-to-left shunting and cyanosis, not isolated gut protein loss. Reference: 2020 ESC Guidelines for the management of adult congenital heart disease.\">D) Eisenmenger Syndrome.<\/button>\n      <\/div>\n      <div class=\"feedback-box hidden p-4 rounded-xl text-sm md:text-base leading-relaxed\"><\/div>\n    <\/div>\n\n    <!-- Q14 -->\n    <div class=\"quiz-card bg-slate-900\/60 border border-solid border-slate-800 rounded-2xl p-5 md:p-6 shadow-lg transition-all duration-300\" data-answered=\"false\">\n      <div class=\"flex items-start gap-3 mb-4\">\n        <span class=\"bg-cyan-950 text-blue-300 font-extrabold px-3 py-1.5 rounded-lg text-sm border border-solid border-cyan-500\/30\">Q14<\/span>\n        <h3 class=\"text-lg md:text-xl font-bold text-slate-100 m-0 leading-snug\">\n          A patient on chronic digoxin therapy for heart failure presents with nausea, visual disturbances (yellow halos), and palpitations. The ECG shows a wide-complex tachycardia with an axis that alternates by 180 degrees beat-to-beat. What is this classic arrhythmia?\n        <\/h3>\n      <\/div>\n      <div class=\"grid grid-cols-1 md:grid-cols-2 gap-3 mb-4\">\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"Torsades is characterized by a twisting morphology around the isoelectric line, usually due to QT prolongation (which digoxin does not cause; digoxin shortens the QT). Reference: 2022 ESC Guidelines for the management of patients with ventricular arrhythmias.\">A) Torsades de Pointes.<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"true\" data-explanation=\"Bidirectional Ventricular Tachycardia (VT) is characterized by a beat-to-beat alternating QRS axis (usually RBBB pattern with alternating left anterior and left posterior fascicular block morphologies). It is highly specific for Digoxin toxicity (and Catecholaminergic Polymorphic Ventricular Tachycardia - CPVT) due to intracellular calcium overload causing delayed afterdepolarizations. Reference: 2022 ESC Guidelines for the management of patients with ventricular arrhythmias.\">B) Bidirectional Ventricular Tachycardia.<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"Fascicular VT is usually monomorphic and does not alternate axis beat-to-beat. Reference: 2022 ESC Guidelines for the management of patients with ventricular arrhythmias.\">C) Left Posterior Fascicular Ventricular Tachycardia.<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"Atrial tachycardia with 2:1 block is common in digoxin toxicity, but presents as a narrow-complex tachycardia, not alternating wide complexes. Reference: 2022 ESC Guidelines for the management of patients with ventricular arrhythmias.\">D) Atrial Tachycardia with 2:1 block.<\/button>\n      <\/div>\n      <div class=\"feedback-box hidden p-4 rounded-xl text-sm md:text-base leading-relaxed\"><\/div>\n    <\/div>\n\n    <!-- Q15 -->\n    <div class=\"quiz-card bg-slate-900\/60 border border-solid border-slate-800 rounded-2xl p-5 md:p-6 shadow-lg transition-all duration-300\" data-answered=\"false\">\n      <div class=\"flex items-start gap-3 mb-4\">\n        <span class=\"bg-cyan-950 text-blue-300 font-extrabold px-3 py-1.5 rounded-lg text-sm border border-solid border-cyan-500\/30\">Q15<\/span>\n        <h3 class=\"text-lg md:text-xl font-bold text-slate-100 m-0 leading-snug\">\n          According to the World Health Organization (WHO) clinical classification of Pulmonary Hypertension (PH), a patient with severe mitral stenosis and secondary pulmonary hypertension belongs to which specific group?\n        <\/h3>\n      <\/div>\n      <div class=\"grid grid-cols-1 md:grid-cols-2 gap-3 mb-4\">\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"Group 1 is Pulmonary Arterial Hypertension (PAH), which includes idiopathic, heritable, or connective tissue disease-associated disease. Reference: 2022 ESC\/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension.\">A) WHO Group 1<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"true\" data-explanation=\"WHO Group 2 represents Pulmonary Hypertension due to Left Heart Disease (including HFrEF, HFpEF, and valvular heart diseases like mitral stenosis). It is the most common cause of pulmonary hypertension globally. Reference: 2022 ESC\/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension.\">B) WHO Group 2<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"Group 3 is PH due to lung diseases or hypoxia (e.g., COPD, ILD, sleep apnea). Reference: 2022 ESC\/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension.\">C) WHO Group 3<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"Group 4 is Chronic Thromboembolic Pulmonary Hypertension (CTEPH). Reference: 2022 ESC\/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension.\">D) WHO Group 4<\/button>\n      <\/div>\n      <div class=\"feedback-box hidden p-4 rounded-xl text-sm md:text-base leading-relaxed\"><\/div>\n    <\/div>\n\n    <!-- Q16 -->\n    <div class=\"quiz-card bg-slate-900\/60 border border-solid border-slate-800 rounded-2xl p-5 md:p-6 shadow-lg transition-all duration-300\" data-answered=\"false\">\n      <div class=\"flex items-start gap-3 mb-4\">\n        <span class=\"bg-cyan-950 text-blue-300 font-extrabold px-3 py-1.5 rounded-lg text-sm border border-solid border-cyan-500\/30\">Q16<\/span>\n        <h3 class=\"text-lg md:text-xl font-bold text-slate-100 m-0 leading-snug\">\n          A patient with Atrial Fibrillation of unknown duration (but definitely &gt; 48 hours) undergoes a successful electrical cardioversion to normal sinus rhythm. Regardless of their baseline CHA2DS2-VASc score, what is the mandatory minimum duration of systemic anticoagulation required POST-cardioversion?\n        <\/h3>\n      <\/div>\n      <div class=\"grid grid-cols-1 md:grid-cols-2 gap-3 mb-4\">\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"1 week is insufficient time for the atria to recover mechanical function. Reference: 2023 ACC\/AHA\/ACCP\/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation.\">A) 1 week.<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"Lifelong anticoagulation is only dictated by the patient's CHA2DS2-VASc score, not solely by the cardioversion itself. Reference: 2023 ACC\/AHA\/ACCP\/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation.\">B) Anticoagulation can be stopped immediately if the CHA2DS2-VASc score is 0.<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"true\" data-explanation=\"Due to 'atrial stunning' (temporary mechanical dysfunction of the atria following restoration of electrical sinus rhythm), the risk of thrombus formation persists. Therefore, full anticoagulation is mandatory for at least 4 weeks post-cardioversion for all patients, after which the need for long-term therapy is dictated by the CHA2DS2-VASc score. Reference: 2023 ACC\/AHA\/ACCP\/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation.\">C) At least 4 weeks.<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"Lifelong therapy depends on the CHA2DS2-VASc score, not just the event of a cardioversion. Reference: 2023 ACC\/AHA\/ACCP\/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation.\">D) Lifelong, irrespective of the CHA2DS2-VASc score.<\/button>\n      <\/div>\n      <div class=\"feedback-box hidden p-4 rounded-xl text-sm md:text-base leading-relaxed\"><\/div>\n    <\/div>\n\n    <!-- Q17 -->\n    <div class=\"quiz-card bg-slate-900\/60 border border-solid border-slate-800 rounded-2xl p-5 md:p-6 shadow-lg transition-all duration-300\" data-answered=\"false\">\n      <div class=\"flex items-start gap-3 mb-4\">\n        <span class=\"bg-cyan-950 text-blue-300 font-extrabold px-3 py-1.5 rounded-lg text-sm border border-solid border-cyan-500\/30\">Q17<\/span>\n        <h3 class=\"text-lg md:text-xl font-bold text-slate-100 m-0 leading-snug\">\n          When a patient experiences In-Stent Restenosis (ISR) months after the deployment of a Bare Metal Stent (BMS), what is the primary pathophysiological mechanism responsible for the re-narrowing?\n        <\/h3>\n      <\/div>\n      <div class=\"grid grid-cols-1 md:grid-cols-2 gap-3 mb-4\">\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"Neoatherosclerosis (formation of new lipid plaques inside the stent) is a late phenomenon primarily seen years later in Drug-Eluting Stents (DES). Reference: 2021 ACC\/AHA\/SCAI Guideline for Coronary Artery Revascularization.\">A) Neoatherosclerosis (new lipid deposition).<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"true\" data-explanation=\"The primary mechanism of in-stent restenosis in Bare Metal Stents (BMS) is excessive neointimal hyperplasia (proliferation and migration of smooth muscle cells into the lumen). This typically peaks at 6 months. Drug-eluting stents were designed specifically with antiproliferative agents to prevent this process. Reference: 2021 ACC\/AHA\/SCAI Guideline for Coronary Artery Revascularization.\">B) Neointimal hyperplasia (smooth muscle cell proliferation).<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"Late stent thrombosis is an acute clotting event often associated with early cessation of antiplatelets or delayed endothelialization (more common in early generation DES), not gradual restenosis. Reference: 2021 ACC\/AHA\/SCAI Guideline for Coronary Artery Revascularization.\">C) Late acute stent thrombosis.<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"Stent fracture is a rare mechanical failure, not the primary biological mechanism of BMS restenosis. Reference: 2021 ACC\/AHA\/SCAI Guideline for Coronary Artery Revascularization.\">D) Stent fracture and mechanical recoil.<\/button>\n      <\/div>\n      <div class=\"feedback-box hidden p-4 rounded-xl text-sm md:text-base leading-relaxed\"><\/div>\n    <\/div>\n\n    <!-- Q18 -->\n    <div class=\"quiz-card bg-slate-900\/60 border border-solid border-slate-800 rounded-2xl p-5 md:p-6 shadow-lg transition-all duration-300\" data-answered=\"false\">\n      <div class=\"flex items-start gap-3 mb-4\">\n        <span class=\"bg-cyan-950 text-blue-300 font-extrabold px-3 py-1.5 rounded-lg text-sm border border-solid border-cyan-500\/30\">Q18<\/span>\n        <h3 class=\"text-lg md:text-xl font-bold text-slate-100 m-0 leading-snug\">\n          Tetralogy of Fallot consists of four classic anatomical features (VSD, Overriding aorta, RVOT obstruction, RV hypertrophy). Which of these features is the primary determinant of the clinical severity and degree of cyanosis?\n        <\/h3>\n      <\/div>\n      <div class=\"grid grid-cols-1 md:grid-cols-2 gap-3 mb-4\">\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"The VSD in ToF is typically large and non-restrictive; it equalizes pressures but does not drive the amount of shunting on its own. Reference: 2020 ESC Guidelines for the management of adult congenital heart disease.\">A) The size of the Ventricular Septal Defect (VSD).<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"true\" data-explanation=\"The degree of Right Ventricular Outflow Tract (RVOT) obstruction (pulmonary stenosis) is the primary determinant of severity in ToF. It dictates the resistance to pulmonary blood flow; severe obstruction forces more deoxygenated blood across the VSD into the systemic circulation (right-to-left shunt), leading to profound cyanosis ('Tet spells'). Reference: 2020 ESC Guidelines for the management of adult congenital heart disease.\">B) The degree of Right Ventricular Outflow Tract (RVOT) obstruction.<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"RV hypertrophy is a secondary consequence of the RV pumping against the obstructed RVOT. Reference: 2020 ESC Guidelines for the management of adult congenital heart disease.\">C) The severity of Right Ventricular Hypertrophy (RVH).<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"The overriding aorta receives the shunted blood, but the degree of override is not the main physiological determinant of cyanosis. Reference: 2020 ESC Guidelines for the management of adult congenital heart disease.\">D) The percentage of aortic override across the septum.<\/button>\n      <\/div>\n      <div class=\"feedback-box hidden p-4 rounded-xl text-sm md:text-base leading-relaxed\"><\/div>\n    <\/div>\n\n    <!-- Q19 -->\n    <div class=\"quiz-card bg-slate-900\/60 border border-solid border-slate-800 rounded-2xl p-5 md:p-6 shadow-lg transition-all duration-300\" data-answered=\"false\">\n      <div class=\"flex items-start gap-3 mb-4\">\n        <span class=\"bg-cyan-950 text-blue-300 font-extrabold px-3 py-1.5 rounded-lg text-sm border border-solid border-cyan-500\/30\">Q19<\/span>\n        <h3 class=\"text-lg md:text-xl font-bold text-slate-100 m-0 leading-snug\">\n          A patient presents to the ER with sharp, pleuritic chest pain that improves upon leaning forward. What are the hallmark ECG findings of Stage 1 Acute Pericarditis?\n        <\/h3>\n      <\/div>\n      <div class=\"grid grid-cols-1 md:grid-cols-2 gap-3 mb-4\">\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"Focal convex ST elevation with reciprocal depression is the hallmark of an acute STEMI, not pericarditis. Reference: 2015 ESC Guidelines for the diagnosis and management of pericardial diseases.\">A) Focal, convex ST segment elevation with reciprocal ST segment depression.<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"true\" data-explanation=\"Stage 1 acute pericarditis is characterized by diffuse, concave-upward ST segment elevations across most leads, coupled with PR segment depression (except in aVR and V1, which often show reciprocal PR elevation and ST depression). Reference: 2015 ESC Guidelines for the diagnosis and management of pericardial diseases.\">B) Diffuse, concave ST segment elevation with PR segment depression.<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"This represents Stage 3 (T wave inversion after the ST segments have normalized) or ischemia. Reference: 2015 ESC Guidelines for the diagnosis and management of pericardial diseases.\">C) Diffuse T wave inversions without ST segment changes.<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"Electrical alternans is a sign of a large pericardial effusion\/tamponade, not Stage 1 acute pericarditis directly. Reference: 2015 ESC Guidelines for the diagnosis and management of pericardial diseases.\">D) Electrical alternans with low voltage QRS complexes.<\/button>\n      <\/div>\n      <div class=\"feedback-box hidden p-4 rounded-xl text-sm md:text-base leading-relaxed\"><\/div>\n    <\/div>\n\n    <!-- Q20 -->\n    <div class=\"quiz-card bg-slate-900\/60 border border-solid border-slate-800 rounded-2xl p-5 md:p-6 shadow-lg transition-all duration-300\" data-answered=\"false\">\n      <div class=\"flex items-start gap-3 mb-4\">\n        <span class=\"bg-cyan-950 text-blue-300 font-extrabold px-3 py-1.5 rounded-lg text-sm border border-solid border-cyan-500\/30\">Q20<\/span>\n        <h3 class=\"text-lg md:text-xl font-bold text-slate-100 m-0 leading-snug\">\n          SGLT2 inhibitors (like Dapagliflozin and Empagliflozin) have transformed heart failure management. Aside from osmotic diuresis, what is proposed as a direct myocardial cellular mechanism for their cardiovascular benefit?\n        <\/h3>\n      <\/div>\n      <div class=\"grid grid-cols-1 md:grid-cols-2 gap-3 mb-4\">\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"true\" data-explanation=\"One of the leading proposed direct myocardial effects of SGLT2 inhibitors is the inhibition of the Sodium-Hydrogen Exchanger 1 (NHE1) in the myocardium. This reduces intracellular sodium and subsequent intracellular calcium overload, improving mitochondrial function and reducing myocardial wall stress. Reference: 2022 AHA\/ACC\/HFSA Guideline for the Management of Heart Failure.\">A) Inhibition of the myocardial Sodium-Hydrogen Exchanger 1 (NHE1), reducing intracellular calcium overload.<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"This describes the mechanism of ARNI (sacubitril). Reference: 2022 AHA\/ACC\/HFSA Guideline for the Management of Heart Failure.\">B) Direct inhibition of neprilysin in the myocardial extracellular matrix.<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"This describes Ivabradine. Reference: 2022 AHA\/ACC\/HFSA Guideline for the Management of Heart Failure.\">C) Blockade of the hyperpolarization-activated &#8216;funny&#8217; current in the SA node.<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"This describes Omecamtiv Mecarbil. Reference: 2022 AHA\/ACC\/HFSA Guideline for the Management of Heart Failure.\">D) Direct allosteric activation of cardiac myosin.<\/button>\n      <\/div>\n      <div class=\"feedback-box hidden p-4 rounded-xl text-sm md:text-base leading-relaxed\"><\/div>\n    <\/div>\n\n    <!-- Q21 -->\n    <div class=\"quiz-card bg-slate-900\/60 border border-solid border-slate-800 rounded-2xl p-5 md:p-6 shadow-lg transition-all duration-300\" data-answered=\"false\">\n      <div class=\"flex items-start gap-3 mb-4\">\n        <span class=\"bg-cyan-950 text-blue-300 font-extrabold px-3 py-1.5 rounded-lg text-sm border border-solid border-cyan-500\/30\">Q21<\/span>\n        <h3 class=\"text-lg md:text-xl font-bold text-slate-100 m-0 leading-snug\">\n          During echocardiographic assessment of left ventricular diastolic function, a &#8220;Restrictive Filling Pattern&#8221; (Grade 3 Diastolic Dysfunction) is characterized by a very stiff left ventricle and markedly elevated left atrial pressure. Which mitral inflow E\/A ratio defines this pattern?\n        <\/h3>\n      <\/div>\n      <div class=\"grid grid-cols-1 md:grid-cols-2 gap-3 mb-4\">\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"An E\/A ratio &lt;= 0.8 is typical of Grade 1 Diastolic Dysfunction (impaired relaxation). Reference: 2016 ASE\/EACVI Guidelines for the Evaluation of Left Ventricular Diastolic Function.\">A) E\/A ratio &lt;= 0.8<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"An E\/A ratio between 0.8 and 2.0 indicates either normal function or Grade 2 (pseudonormal) diastolic dysfunction. Reference: 2016 ASE\/EACVI Guidelines for the Evaluation of Left Ventricular Diastolic Function.\">B) E\/A ratio between 0.8 and 2.0<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"true\" data-explanation=\"A restrictive filling pattern (Grade 3) occurs when severe LV stiffness drives up left atrial pressure. This causes a massive, rapid early rush of blood (tall E wave), followed by very little late filling (small A wave) because the LV is completely full and stiff. This results in an E\/A ratio &gt;= 2.0 with a rapid deceleration time (&lt; 160 ms). Reference: 2016 ASE\/EACVI Guidelines for the Evaluation of Left Ventricular Diastolic Function.\">C) E\/A ratio &gt;= 2.0<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"E\/A ratio is not defined by E' values; E\/e' is a separate tissue doppler measurement. Reference: 2016 ASE\/EACVI Guidelines for the Evaluation of Left Ventricular Diastolic Function.\">D) The E\/A ratio must be mathematically identical to the lateral e&#8217; wave.<\/button>\n      <\/div>\n      <div class=\"feedback-box hidden p-4 rounded-xl text-sm md:text-base leading-relaxed\"><\/div>\n    <\/div>\n\n    <!-- Q22 -->\n    <div class=\"quiz-card bg-slate-900\/60 border border-solid border-slate-800 rounded-2xl p-5 md:p-6 shadow-lg transition-all duration-300\" data-answered=\"false\">\n      <div class=\"flex items-start gap-3 mb-4\">\n        <span class=\"bg-cyan-950 text-blue-300 font-extrabold px-3 py-1.5 rounded-lg text-sm border border-solid border-cyan-500\/30\">Q22<\/span>\n        <h3 class=\"text-lg md:text-xl font-bold text-slate-100 m-0 leading-snug\">\n          A CT scan reveals an acute Stanford Type B Aortic Dissection in a hemodynamically stable patient without end-organ malperfusion or intractable pain. What is the standard, first-line management?\n        <\/h3>\n      <\/div>\n      <div class=\"grid grid-cols-1 md:grid-cols-2 gap-3 mb-4\">\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"This is the emergency treatment for a Type A dissection (involving the ascending aorta). Reference: 2022 ACC\/AHA Guideline for the Diagnosis and Management of Aortic Disease.\">A) Immediate open surgical repair with a Dacron graft.<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"TEVAR is reserved for COMPLICATED Type B dissections (e.g., rapid expansion, malperfusion, refractory pain). Reference: 2022 ACC\/AHA Guideline for the Diagnosis and Management of Aortic Disease.\">B) Urgent Thoracic Endovascular Aortic Repair (TEVAR).<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"true\" data-explanation=\"Uncomplicated Stanford Type B aortic dissections (distal to the left subclavian artery) are treated medically with aggressive 'anti-impulse' therapy. The goal is to lower heart rate (&lt; 60 bpm) and blood pressure (Systolic &lt; 120 mmHg), strictly using intravenous Beta-Blockers (e.g., Esmolol or Labetalol) as the first step. Reference: 2022 ACC\/AHA Guideline for the Diagnosis and Management of Aortic Disease.\">C) Aggressive medical management with intravenous Beta-Blockers (Anti-impulse therapy).<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"Anticoagulation is strongly contraindicated as it can expand the false lumen and cause fatal hemorrhage. Reference: 2022 ACC\/AHA Guideline for the Diagnosis and Management of Aortic Disease.\">D) Systemic anticoagulation with intravenous Heparin.<\/button>\n      <\/div>\n      <div class=\"feedback-box hidden p-4 rounded-xl text-sm md:text-base leading-relaxed\"><\/div>\n    <\/div>\n\n    <!-- Q23 -->\n    <div class=\"quiz-card bg-slate-900\/60 border border-solid border-slate-800 rounded-2xl p-5 md:p-6 shadow-lg transition-all duration-300\" data-answered=\"false\">\n      <div class=\"flex items-start gap-3 mb-4\">\n        <span class=\"bg-cyan-950 text-blue-300 font-extrabold px-3 py-1.5 rounded-lg text-sm border border-solid border-cyan-500\/30\">Q23<\/span>\n        <h3 class=\"text-lg md:text-xl font-bold text-slate-100 m-0 leading-snug\">\n          According to international STEMI guidelines, for a patient presenting directly to a PCI-capable hospital, what is the maximum recommended First Medical Contact (FMC)-to-Device (door-to-balloon) time goal?\n        <\/h3>\n      <\/div>\n      <div class=\"grid grid-cols-1 md:grid-cols-2 gap-3 mb-4\">\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"This is the target time for FMC-to-Wire if the patient transfers from a NON-PCI capable hospital. Reference: 2023 ESC Guidelines for the management of ACS.\">A) &lt;= 120 minutes<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"true\" data-explanation=\"For patients presenting to a hospital that is capable of performing percutaneous coronary intervention (PCI), guidelines mandate that the wire\/device should cross the culprit lesion within 90 minutes of First Medical Contact. Reference: 2023 ESC Guidelines for the management of ACS.\">B) &lt;= 90 minutes<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"30 minutes is the target time for administering fibrinolytics (door-to-needle time) if PCI cannot be achieved in 120 mins. Reference: 2023 ESC Guidelines for the management of ACS.\">C) &lt;= 30 minutes<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"This is too lenient; 90 minutes is the strict gold-standard. Reference: 2023 ESC Guidelines for the management of ACS.\">D) &lt;= 180 minutes<\/button>\n      <\/div>\n      <div class=\"feedback-box hidden p-4 rounded-xl text-sm md:text-base leading-relaxed\"><\/div>\n    <\/div>\n\n    <!-- Q24 -->\n    <div class=\"quiz-card bg-slate-900\/60 border border-solid border-slate-800 rounded-2xl p-5 md:p-6 shadow-lg transition-all duration-300\" data-answered=\"false\">\n      <div class=\"flex items-start gap-3 mb-4\">\n        <span class=\"bg-cyan-950 text-blue-300 font-extrabold px-3 py-1.5 rounded-lg text-sm border border-solid border-cyan-500\/30\">Q24<\/span>\n        <h3 class=\"text-lg md:text-xl font-bold text-slate-100 m-0 leading-snug\">\n          When screening a patient for Transcatheter Edge-to-Edge Repair (TEER \/ MitraClip) for severe mitral regurgitation, which anatomical criterion must be met to avoid creating clinically significant iatrogenic mitral stenosis?\n        <\/h3>\n      <\/div>\n      <div class=\"grid grid-cols-1 md:grid-cols-2 gap-3 mb-4\">\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"An area &gt;= 1.5 cm\u00b2 is too small; clipping would immediately cause severe MS. Reference: 2020 ACC\/AHA Guideline for the Management of Patients With Valvular Heart Disease.\">A) Mitral Valve Area &gt;= 1.5 cm\u00b2<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"Mitral annular calcification makes TEER technically challenging, but the critical hard cutoff for MS prevention is the starting valve area. Reference: 2020 ACC\/AHA Guideline for the Management of Patients With Valvular Heart Disease.\">B) Complete absence of any mitral annular calcification (MAC).<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"true\" data-explanation=\"Placing a clip creates a double-orifice mitral valve, inherently reducing the total valve area by about 50%. Therefore, to prevent creating symptomatic mitral stenosis, the baseline Mitral Valve Area (MVA) should be &gt;= 3.0 to 4.0 cm\u00b2 (guidelines generally require an MVA &gt; 4.0 cm\u00b2 for ideal anatomy, but &gt; 3.0 cm\u00b2 is often cited as the absolute minimum in practice). Reference: 2020 ACC\/AHA Guideline for the Management of Patients With Valvular Heart Disease.\">C) Mitral Valve Area &gt;= 3.0 cm\u00b2 to 4.0 cm\u00b2<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"A flail gap &gt; 10mm makes the procedure very difficult or impossible to grasp the leaflets, but this is a criterion for MR reduction success, not for preventing MS. Reference: 2020 ACC\/AHA Guideline for the Management of Patients With Valvular Heart Disease.\">D) A flail gap &gt; 10 mm<\/button>\n      <\/div>\n      <div class=\"feedback-box hidden p-4 rounded-xl text-sm md:text-base leading-relaxed\"><\/div>\n    <\/div>\n\n    <!-- Q25 -->\n    <div class=\"quiz-card bg-slate-900\/60 border border-solid border-slate-800 rounded-2xl p-5 md:p-6 shadow-lg transition-all duration-300\" data-answered=\"false\">\n      <div class=\"flex items-start gap-3 mb-4\">\n        <span class=\"bg-cyan-950 text-blue-300 font-extrabold px-3 py-1.5 rounded-lg text-sm border border-solid border-cyan-500\/30\">Q25<\/span>\n        <h3 class=\"text-lg md:text-xl font-bold text-slate-100 m-0 leading-snug\">\n          In patients who have undergone Orthotopic Heart Transplantation, what is the &#8216;gold standard&#8217; test utilized for the routine surveillance and diagnosis of acute cellular rejection?\n        <\/h3>\n      <\/div>\n      <div class=\"grid grid-cols-1 md:grid-cols-2 gap-3 mb-4\">\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"While strain echo is useful for detecting late graft dysfunction, it is not the gold standard for diagnosing acute cellular rejection. Reference: ISHLT Guidelines for the Care of Heart Transplant Recipients.\">A) Global Longitudinal Strain (GLS) on Transthoracic Echocardiography.<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"Cardiac MRI is not the routine standard for frequent post-transplant rejection surveillance. Reference: ISHLT Guidelines for the Care of Heart Transplant Recipients.\">B) Cardiac MRI with T2 mapping for myocardial edema.<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"true\" data-explanation=\"The Endomyocardial Biopsy (EMB), typically performed via the right internal jugular vein taking samples from the right ventricular septum, remains the gold standard for grading both acute cellular rejection and antibody-mediated rejection in heart transplant recipients. Reference: ISHLT Guidelines for the Care of Heart Transplant Recipients.\">C) Right Ventricular Endomyocardial Biopsy.<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"Allomap is a non-invasive genomic test used to rule out rejection in low-risk patients, but biopsy remains the gold standard for definitive diagnosis. Reference: ISHLT Guidelines for the Care of Heart Transplant Recipients.\">D) Peripheral blood gene expression profiling (Allomap) alone.<\/button>\n      <\/div>\n      <div class=\"feedback-box hidden p-4 rounded-xl text-sm md:text-base leading-relaxed\"><\/div>\n    <\/div>\n\n  <\/div>\n<\/div>\n\n<script>\n  let mcq17Correct = 0;\n  let mcq17Answered = 0;\n  const mcq17Total = 25;\n\n  document.querySelectorAll('#mcq17-quiz-wrapper .quiz-card').forEach(card => {\n    const buttons = card.querySelectorAll('.opt-btn');\n    buttons.forEach(btn => {\n      btn.addEventListener('click', function() {\n        if (card.getAttribute('data-answered') === 'true') return;\n        card.setAttribute('data-answered', 'true');\n        mcq17Answered++;\n\n        document.getElementById('mcq17-answered-count').innerText = mcq17Answered;\n        const pct = (mcq17Answered \/ mcq17Total) * 100;\n        document.getElementById('mcq17-progress-bar').style.width = pct + '%';\n\n        buttons.forEach(b => {\n          b.disabled = true;\n          b.classList.remove('hover:bg-slate-900', 'cursor-pointer');\n          b.classList.add('opacity-50', 'cursor-not-allowed');\n        });\n\n        const isCorrect = this.getAttribute('data-correct') === 'true';\n        const explanation = this.getAttribute('data-explanation');\n\n        if (isCorrect) {\n          mcq17Correct++;\n          document.getElementById('mcq17-correct-count').innerText = mcq17Correct;\n          this.classList.remove('opacity-50', 'border-slate-800', 'bg-slate-950');\n          this.classList.add('bg-emerald-950\/80', 'border-emerald-500', 'text-emerald-200', 'opacity-100', 'border-2');\n          this.innerHTML += ' <span class=\"font-bold\">&#10004; CORRECT!<\/span>';\n        } else {\n          this.classList.remove('opacity-50', 'border-slate-800', 'bg-slate-950');\n          this.classList.add('bg-red-950\/80', 'border-red-500', 'text-red-200', 'opacity-100', 'border-2');\n          this.innerHTML += ' <span class=\"font-bold\">&#10006; INCORRECT<\/span>';\n\n          buttons.forEach(b => {\n            if (b.getAttribute('data-correct') === 'true') {\n              b.classList.remove('opacity-50', 'border-slate-800', 'bg-slate-950');\n              b.classList.add('bg-emerald-950\/40', 'border-emerald-500\/55', 'text-emerald-200', 'opacity-100', 'border-2');\n              b.innerHTML += ' <span class=\"font-bold\">&#10004; (Correct)<\/span>';\n            }\n          });\n        }\n\n        const feedback = card.querySelector('.feedback-box');\n        feedback.innerHTML = `\n          <div class=\"font-extrabold uppercase tracking-widest text-xs mb-2 ${isCorrect ? 'text-emerald-400' : 'text-red-400'}\">\n            ${isCorrect ? 'Clinical Explanation & Reference' : 'Explanation, Correct Answer & Reference'}\n          <\/div>\n          <p class=\"m-0\">${explanation}<\/p>\n        `;\n        feedback.classList.remove('hidden');\n        feedback.classList.add('block', isCorrect ? 'bg-emerald-950\/45' : 'bg-red-950\/20', 'border-2', 'border-solid', isCorrect ? 'border-emerald-500\/30' : 'border-red-500\/30', 'text-slate-200', 'mt-4');\n      });\n    });\n  });\n<\/script>\n","protected":false},"excerpt":{"rendered":"<p>\ud83e\udec0 Advanced Cardiology Series &#8211; Part 17 Interactive Cardiology MCQs #17 Post-Graduate Level Clinical, EP, Structural &amp; Hemodynamics Masterclass \ud83c\udfc5 Live Scoreboard 0\/ 25 Correct Progress: 0\/25 Q1 During coronary angiography, Fractional Flow Reserve (FFR) is measured to assess the hemodynamic significance of an intermediate coronary stenosis. What is the standard FFR cut-off value below [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":68004,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"nf_dc_page":"","footnotes":""},"categories":[9],"tags":[],"class_list":["post-68003","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-general"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>New Series of Interactive Cardiology MCQs 17 - All About Cardiovascular System and Disorders<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/johnsonfrancis.org\/professional\/new-series-of-interactive-cardiology-mcqs-17\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"New Series of Interactive Cardiology MCQs 17 - All About Cardiovascular System and Disorders\" \/>\n<meta property=\"og:description\" content=\"\ud83e\udec0 Advanced Cardiology Series &#8211; Part 17 Interactive Cardiology MCQs #17 Post-Graduate Level Clinical, EP, Structural &amp; Hemodynamics Masterclass \ud83c\udfc5 Live Scoreboard 0\/ 25 Correct Progress: 0\/25 Q1 During coronary angiography, Fractional Flow Reserve (FFR) is measured to assess the hemodynamic significance of an intermediate coronary stenosis. What is the standard FFR cut-off value below [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/johnsonfrancis.org\/professional\/new-series-of-interactive-cardiology-mcqs-17\/\" \/>\n<meta property=\"og:site_name\" content=\"All About Cardiovascular System and Disorders\" \/>\n<meta property=\"article:published_time\" content=\"2026-10-28T13:42:54+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-10-28T13:43:00+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/johnsonfrancis.org\/professional\/wp-content\/uploads\/2026\/10\/New-Series-of-Interactive-Cardiology-MCQs-17.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1208\" \/>\n\t<meta property=\"og:image:height\" content=\"675\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Johnson Francis\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Johnson Francis\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"9 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/new-series-of-interactive-cardiology-mcqs-17\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/new-series-of-interactive-cardiology-mcqs-17\\\/\"},\"author\":{\"name\":\"Johnson Francis\",\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/#\\\/schema\\\/person\\\/5441d907049b914770f4bd98fb57feec\"},\"headline\":\"New Series of Interactive Cardiology MCQs 17\",\"datePublished\":\"2026-10-28T13:42:54+00:00\",\"dateModified\":\"2026-10-28T13:43:00+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/new-series-of-interactive-cardiology-mcqs-17\\\/\"},\"wordCount\":1590,\"publisher\":{\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/#\\\/schema\\\/person\\\/5441d907049b914770f4bd98fb57feec\"},\"image\":{\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/new-series-of-interactive-cardiology-mcqs-17\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/wp-content\\\/uploads\\\/2026\\\/10\\\/New-Series-of-Interactive-Cardiology-MCQs-17.jpg\",\"articleSection\":[\"General Cardiology\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/new-series-of-interactive-cardiology-mcqs-17\\\/\",\"url\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/new-series-of-interactive-cardiology-mcqs-17\\\/\",\"name\":\"New Series of Interactive Cardiology MCQs 17 - All About Cardiovascular System and Disorders\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/new-series-of-interactive-cardiology-mcqs-17\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/new-series-of-interactive-cardiology-mcqs-17\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/wp-content\\\/uploads\\\/2026\\\/10\\\/New-Series-of-Interactive-Cardiology-MCQs-17.jpg\",\"datePublished\":\"2026-10-28T13:42:54+00:00\",\"dateModified\":\"2026-10-28T13:43:00+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/new-series-of-interactive-cardiology-mcqs-17\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/new-series-of-interactive-cardiology-mcqs-17\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/new-series-of-interactive-cardiology-mcqs-17\\\/#primaryimage\",\"url\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/wp-content\\\/uploads\\\/2026\\\/10\\\/New-Series-of-Interactive-Cardiology-MCQs-17.jpg\",\"contentUrl\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/wp-content\\\/uploads\\\/2026\\\/10\\\/New-Series-of-Interactive-Cardiology-MCQs-17.jpg\",\"width\":1208,\"height\":675},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/new-series-of-interactive-cardiology-mcqs-17\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"New Series of Interactive Cardiology MCQs 17\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/#website\",\"url\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/\",\"name\":\"All About Cardiovascular System and Disorders\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/#\\\/schema\\\/person\\\/5441d907049b914770f4bd98fb57feec\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":[\"Person\",\"Organization\"],\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/#\\\/schema\\\/person\\\/5441d907049b914770f4bd98fb57feec\",\"name\":\"Johnson Francis\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/80861b82c3f559be9e413245c5643b6c483c93495507facfe32cf96ccd8bcffd?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/80861b82c3f559be9e413245c5643b6c483c93495507facfe32cf96ccd8bcffd?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/80861b82c3f559be9e413245c5643b6c483c93495507facfe32cf96ccd8bcffd?s=96&d=mm&r=g\",\"caption\":\"Johnson Francis\"},\"logo\":{\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/80861b82c3f559be9e413245c5643b6c483c93495507facfe32cf96ccd8bcffd?s=96&d=mm&r=g\"},\"description\":\"Former Professor of Cardiology, Calicut Govt. Medical Kozhikode, Kerala, India. Editor-in-Chief, BMH Medical Journal\",\"url\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/author\\\/jf\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"New Series of Interactive Cardiology MCQs 17 - All About Cardiovascular System and Disorders","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/johnsonfrancis.org\/professional\/new-series-of-interactive-cardiology-mcqs-17\/","og_locale":"en_US","og_type":"article","og_title":"New Series of Interactive Cardiology MCQs 17 - All About Cardiovascular System and Disorders","og_description":"\ud83e\udec0 Advanced Cardiology Series &#8211; Part 17 Interactive Cardiology MCQs #17 Post-Graduate Level Clinical, EP, Structural &amp; Hemodynamics Masterclass \ud83c\udfc5 Live Scoreboard 0\/ 25 Correct Progress: 0\/25 Q1 During coronary angiography, Fractional Flow Reserve (FFR) is measured to assess the hemodynamic significance of an intermediate coronary stenosis. What is the standard FFR cut-off value below [&hellip;]","og_url":"https:\/\/johnsonfrancis.org\/professional\/new-series-of-interactive-cardiology-mcqs-17\/","og_site_name":"All About Cardiovascular System and Disorders","article_published_time":"2026-10-28T13:42:54+00:00","article_modified_time":"2026-10-28T13:43:00+00:00","og_image":[{"width":1208,"height":675,"url":"https:\/\/johnsonfrancis.org\/professional\/wp-content\/uploads\/2026\/10\/New-Series-of-Interactive-Cardiology-MCQs-17.jpg","type":"image\/jpeg"}],"author":"Johnson Francis","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Johnson Francis","Est. reading time":"9 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/johnsonfrancis.org\/professional\/new-series-of-interactive-cardiology-mcqs-17\/#article","isPartOf":{"@id":"https:\/\/johnsonfrancis.org\/professional\/new-series-of-interactive-cardiology-mcqs-17\/"},"author":{"name":"Johnson Francis","@id":"https:\/\/johnsonfrancis.org\/professional\/#\/schema\/person\/5441d907049b914770f4bd98fb57feec"},"headline":"New Series of Interactive Cardiology MCQs 17","datePublished":"2026-10-28T13:42:54+00:00","dateModified":"2026-10-28T13:43:00+00:00","mainEntityOfPage":{"@id":"https:\/\/johnsonfrancis.org\/professional\/new-series-of-interactive-cardiology-mcqs-17\/"},"wordCount":1590,"publisher":{"@id":"https:\/\/johnsonfrancis.org\/professional\/#\/schema\/person\/5441d907049b914770f4bd98fb57feec"},"image":{"@id":"https:\/\/johnsonfrancis.org\/professional\/new-series-of-interactive-cardiology-mcqs-17\/#primaryimage"},"thumbnailUrl":"https:\/\/johnsonfrancis.org\/professional\/wp-content\/uploads\/2026\/10\/New-Series-of-Interactive-Cardiology-MCQs-17.jpg","articleSection":["General Cardiology"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/johnsonfrancis.org\/professional\/new-series-of-interactive-cardiology-mcqs-17\/","url":"https:\/\/johnsonfrancis.org\/professional\/new-series-of-interactive-cardiology-mcqs-17\/","name":"New Series of Interactive Cardiology MCQs 17 - All About Cardiovascular System and Disorders","isPartOf":{"@id":"https:\/\/johnsonfrancis.org\/professional\/#website"},"primaryImageOfPage":{"@id":"https:\/\/johnsonfrancis.org\/professional\/new-series-of-interactive-cardiology-mcqs-17\/#primaryimage"},"image":{"@id":"https:\/\/johnsonfrancis.org\/professional\/new-series-of-interactive-cardiology-mcqs-17\/#primaryimage"},"thumbnailUrl":"https:\/\/johnsonfrancis.org\/professional\/wp-content\/uploads\/2026\/10\/New-Series-of-Interactive-Cardiology-MCQs-17.jpg","datePublished":"2026-10-28T13:42:54+00:00","dateModified":"2026-10-28T13:43:00+00:00","breadcrumb":{"@id":"https:\/\/johnsonfrancis.org\/professional\/new-series-of-interactive-cardiology-mcqs-17\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/johnsonfrancis.org\/professional\/new-series-of-interactive-cardiology-mcqs-17\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/johnsonfrancis.org\/professional\/new-series-of-interactive-cardiology-mcqs-17\/#primaryimage","url":"https:\/\/johnsonfrancis.org\/professional\/wp-content\/uploads\/2026\/10\/New-Series-of-Interactive-Cardiology-MCQs-17.jpg","contentUrl":"https:\/\/johnsonfrancis.org\/professional\/wp-content\/uploads\/2026\/10\/New-Series-of-Interactive-Cardiology-MCQs-17.jpg","width":1208,"height":675},{"@type":"BreadcrumbList","@id":"https:\/\/johnsonfrancis.org\/professional\/new-series-of-interactive-cardiology-mcqs-17\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/johnsonfrancis.org\/professional\/"},{"@type":"ListItem","position":2,"name":"New Series of Interactive Cardiology MCQs 17"}]},{"@type":"WebSite","@id":"https:\/\/johnsonfrancis.org\/professional\/#website","url":"https:\/\/johnsonfrancis.org\/professional\/","name":"All About Cardiovascular System and Disorders","description":"","publisher":{"@id":"https:\/\/johnsonfrancis.org\/professional\/#\/schema\/person\/5441d907049b914770f4bd98fb57feec"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/johnsonfrancis.org\/professional\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":["Person","Organization"],"@id":"https:\/\/johnsonfrancis.org\/professional\/#\/schema\/person\/5441d907049b914770f4bd98fb57feec","name":"Johnson Francis","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/80861b82c3f559be9e413245c5643b6c483c93495507facfe32cf96ccd8bcffd?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/80861b82c3f559be9e413245c5643b6c483c93495507facfe32cf96ccd8bcffd?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/80861b82c3f559be9e413245c5643b6c483c93495507facfe32cf96ccd8bcffd?s=96&d=mm&r=g","caption":"Johnson Francis"},"logo":{"@id":"https:\/\/secure.gravatar.com\/avatar\/80861b82c3f559be9e413245c5643b6c483c93495507facfe32cf96ccd8bcffd?s=96&d=mm&r=g"},"description":"Former Professor of Cardiology, Calicut Govt. Medical Kozhikode, Kerala, India. Editor-in-Chief, BMH Medical Journal","url":"https:\/\/johnsonfrancis.org\/professional\/author\/jf\/"}]}},"amp_enabled":true,"_links":{"self":[{"href":"https:\/\/johnsonfrancis.org\/professional\/wp-json\/wp\/v2\/posts\/68003","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/johnsonfrancis.org\/professional\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/johnsonfrancis.org\/professional\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/johnsonfrancis.org\/professional\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/johnsonfrancis.org\/professional\/wp-json\/wp\/v2\/comments?post=68003"}],"version-history":[{"count":1,"href":"https:\/\/johnsonfrancis.org\/professional\/wp-json\/wp\/v2\/posts\/68003\/revisions"}],"predecessor-version":[{"id":68005,"href":"https:\/\/johnsonfrancis.org\/professional\/wp-json\/wp\/v2\/posts\/68003\/revisions\/68005"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/johnsonfrancis.org\/professional\/wp-json\/wp\/v2\/media\/68004"}],"wp:attachment":[{"href":"https:\/\/johnsonfrancis.org\/professional\/wp-json\/wp\/v2\/media?parent=68003"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/johnsonfrancis.org\/professional\/wp-json\/wp\/v2\/categories?post=68003"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/johnsonfrancis.org\/professional\/wp-json\/wp\/v2\/tags?post=68003"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}